News

Up to 500,000 doses of the vaccine will be manufactured, and the first doses will be available in September. ASD Specialty Healthcare and its Besse Medical and Oncology

Orphan status for Betalutin will provide the company several advantages, such as reduced costs related to the clinical development program, as well as commercial exclusivity for ten years

Under the IND application, the company will be able to move forward in the third quarter of 2014 with its planned US-based Phase II clinical trial designed to

Livatag was already patented until 2019 with a first patent family covering the pharmaceutical product’s composition. The second one covers the specific administration scheme of Livatag, strengthening and

These three antigens are in addition to the Company’s agglutinin-like sequence 3 (Als3) antigen used in NDV-3, NovaDigm’s lead vaccine being evaluated in an on-going Phase 1b/2a study.

PaxVax will license intellectual property and work together with Deborah Spector, Ph.D., distinguished professor in the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and the

The results indicated that Lymphoseek sensitivity for sentinel lymph node mapping was consistent across the tumor type studies, regardless of whether surgery was conducted on the same day

The studies are designed to assess the efficacy and safety of ALKS 5461 in patients suffering from MDD who have had an inadequate response to commonly prescribed drugs,

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the initial